BioCentury | Jan 3, 2019
Distillery Therapeutics

Cardiovascular

...with normal TRPM2 expression. In another mouse model of cerebral ischemia/reperfusion injury, administration of Cymbalta duloxetine...
...increased mobility-related neurological scores compared with vehicle. Next steps could include testing the safety of Cymbalta...
...Cymbalta to manage fibromyalgia syndrome and treat anxiety, depression and pain. Eli Lilly also markets Cymbalta...
BioCentury | Jul 24, 2018
Company News

Lilly again beats revenue estimates, raises full-year guidance

...drugs Humalog insulin lispro and Trulicity dulaglutide, oncology drug Erbitux cetuximab and neurology product Cymbalta duloxetine...
BioCentury | Jun 27, 2017
Distillery Techniques

Biomarkers

...miR-146b-5p and miR-425-3p were lower than in unaffected subjects. In 124 patients treated with Cymbalta duloxetine...
...pathways downstream of the miRNAs. Eli Lilly and Co. and Shionogi & Co. Ltd. market Cymbalta...
BioCentury | Dec 21, 2016
Clinical News

Cymbalta regulatory update

...Shionogi and Eli Lilly said Japan approved an expanded label for Cymbalta duloxetine to include treatment...
...and chronic lower back pain. In 2007, Shionogi and Lilly partnered to co-develop and co-commercialize Cymbalta...
...Tokyo:4507), Osaka, Japan Product: Cymbalta duloxetine ( Ariclaim , Xeristar , Yentreve) (LY248686) Business: Neurology Julian Zhu Ariclaim Cymbalta duloxetine LY248686 Xeristar Yentreve Eli...
BioCentury | Oct 24, 2016
Strategy

Lilly’s history lesson

...sales in 2007, while Cymbalta produced $2.1 billion. Patents on Zyprexa expired in 2011, and Cymbalta...
...the gaps from blockbuster patent expirations including cancer drug Gemzar gemcitabine and CNS drugs Cymbalta duloxetine...
...E. “Blooming at both ends.” BioCentury (2008) Schaeffer, S. “CEO of the future.” BioCentury (2013) Erin McCallister Cialis Cymbalta Cyramza Jardiance Taltz Trulicity Eli...
BioCentury | Mar 21, 2016
Finance

Stress test

...but nobody has solved the puzzle." Eli Lilly and Co. (NYSE:LLY) sells depression drug Cymbalta duloxetine...
...But the pharma pulled an NDA for the indication at FDA about a decade ago. "Duloxetine...
BioCentury | Jun 8, 2015
Clinical News

Cymbalta duloxetine regulatory update

...Shionogi and Lilly said Japan approved an expanded label for Cymbalta duloxetine to include the treatment...
...pain associated with diabetic neuropathy. In 2007, Shionogi and Lilly partnered to co-develop and co-commercialize Cymbalta...
...Co. (NYSE:LLY), Indianapolis, Ind. Product: Cymbalta duloxetine ( Ariclaim , Xeristar , Yentreve ) ( LY248686...
BioCentury | Oct 27, 2014
Finance

Waiting for better times

...$4.83B estimate. The pharma attributed the drop to patent expirations. Sales of neurology drug Cymbalta duloxetine...
BioCentury | Jul 28, 2014
Finance

Staying the course with half a billion

...to lower sales volume, lower drug prices and currency exchange. Sales of neurology drug Cymbalta duloxetine...
BioCentury | Jul 28, 2014
Clinical News

Brintellix vortioxetine: Phase II data

...Additionally, Brintellix significantly improved MADRS (p<0.05) and UPSA (p<0.001) scores vs. placebo. The active comparator duloxetine...
...see BioCentury, Sept. 10, 2007). Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets duloxetine as Cymbalta...
Items per page:
1 - 10 of 197